Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).

NCT04372953 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-05-04
Last updated
2026-02-19

Condition(s) studied

Lung InjuryPreterm Birth

Investigational drug(s) / intervention(s)

Positive End-Expiratory Pressure (PEEP)

Positive End-Expiratory Pressure (PEEP): PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of: 1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort. 2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV).

Study summary

Premature babies often need help immediately after birth to open their lungs to air, start breathing and keep their hearts beating. Opening their lungs can be difficult, and once open the under-developed lungs of premature babies will often collapse again between each breath. To prevent this nearly all premature babies receive some form of mechanical respiratory support to aid breathing. Common to all types of respiratory support is the delivery of a treatment called positive end-expiratory pressure, or PEEP. PEEP gives air, or a mixture of air and oxygen, to the lung between each breath to keep the lungs open and stop them collapsing.

Currently, clinicians do not have enough evidence on the right amount, or level, of PEEP to give at birth. As a result, doctors around the world give different amounts (or levels) of PEEP to premature babies at birth.

In this study, the Investigators will look at 2 different approaches to PEEP to help premature babies during their first breaths at birth. At the moment, the Investigators do not know if one is better than the other. One is to give the same PEEP level to the lungs. The others is to give a high PEEP level at birth when the lungs are hardest to open and then decrease the PEEP later once the lungs are opened and the baby is breathing.

Very premature babies have a risk of long-term lung disease (chronic lung disease). The more breathing support a premature baby needs, the more likely the risk of developing chronic lung disease. The Investigators want to find out whether one method of opening the baby's lungs at birth results in them needing less breathing support.

This research has been initiated by a group of doctors from Australia, the Netherlands and the USA, all who look after premature babies.

Eligibility

Sex
ALL
Min age
23 Weeks
Max age
28 Weeks
Healthy volunteers
No
Inclusion Criteria: * Infants born between 23 weeks 0 days and 28 weeks 6 days PMA (by best obstetric estimate). * Receives respiratory intervention (resuscitation) at birth with CPAP and/or positive pressure ventilation in the Delivery Room, to support transition and/or respiratory failure related to prematurity. * Has a parent or other legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf either prospectively or after birth and randomisation if prenatal consent was not possible (at sites where the Ethics Committee permits waiver of prospective consent). Exclusion Criteria: * Not for active care based on assessment of the attending clinician or family decision * Anticipated severe pulmonary hypoplasia due to rupture of membranes \<22 weeks with anhydramnios or fetal hydrops * Major congenital anomaly or anticipated alternative cause for respiratory failure * Refusal of informed consent by their legally acceptable representative * Does not have a guardian who can provide informed consent.

Primary outcome measure(s)

  • The prevalence of the composite outcome of either death or bronchopulmonary dysplasia (BPD), as assessed by standard oxygen reduction test. — At 36 weeks post menstrual age.
    This is defined as the proportion of participants in the analysis set with a confirmed death date or a diagnosis of bronchopulmonary dysplasia (BPD), at 36 weeks post menstrual age.

Trial sites (27)

FacilityCityRegionStatus
University of Arkansas for Medical Sciences Little Rock Arkansas
Sharp Mary Birch Hospital for Women & Newborns San Diego California
Indiana University / Riley Children Health at Indiana University Health Indianapolis Indiana
Hospital of the University of Pennsylvania Philadelphia Pennsylvania
Mater Misericordiae South Brisbane Queensland
Women & Childrens Hospital Adelaide Adelaide South Australia
Joan Kirner Women & Children's Hospital - VIC Melbourne Victoria
The Royal Women's Hospital, Melbourne Australia Parkville Victoria
King Edward Memorial Hospital Subiaco Western Australia
Academic Teaching Hospital Feldkirch Austria
Antoine Beclere Medical Center / South Paris University Hospitals Paris France
San Gerardo Hospital Monza Milan
Filippo del Ponte Hospital Varese Milan
Careggi Hospital Florence Italy
Ospedale Maggiore Policlinico Milan Italy
Vittore Buzzi Children's Hospital / Ospedale dei Bambini Milan Italy
Gemelli University Hospital Rome Italy
Amsterdam University Medical Centre Amsterdam Netherlands
Amalia Children's Hospital Radboudumc Nijmegen Netherlands
Maxima Medical Centre Veldhoven Netherlands
Birmingham Heartlands Hospital Birmingham England
Southmead Hospital Bristol England
James Cook University Hospital Middlesbrough England
Royal Infirmary Edinburgh Edinburgh Scotland
Royal Hospital for Children Glasgow Scotland
University Hospital Wishaw Wishaw Scotland
University Hospitals Leicester Leicester United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04372953 on ClinicalTrials.gov ↗ ← All trials in France